{"id":"https://openalex.org/W2002810554","doi":"https://doi.org/10.2174/187152008783497064","title":"Recent Advances in Classical and Non-Classical Antifolates as Antitumor and Antiopportunistic Infection Agents: Part II","display_name":"Recent Advances in Classical and Non-Classical Antifolates as Antitumor and Antiopportunistic Infection Agents: Part II","alternate_titles":[],"publication_year":2008,"publication_date":"2008-02-01","ids":{"openalex":"https://openalex.org/W2002810554","doi":"https://doi.org/10.2174/187152008783497064","mag":"2002810554","pmid":"https://pubmed.ncbi.nlm.nih.gov/18288923"},"language":"en","primary_location":{"id":"doi:10.2174/187152008783497064","doi":"https://doi.org/10.2174/187152008783497064","is_oa":false,"landing_page_url":"https://doi.org/10.2174/187152008783497064","pdf_url":null,"source":{"id":"https://openalex.org/S159246083","display_name":"Anti-Cancer Agents in Medicinal Chemistry","issn_l":"1568-0118","issn":["1568-0118","1871-5206","1875-5968","1875-5992"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-3"],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anti-Cancer Agents in Medicinal Chemistry","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2002810554"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5052708209","display_name":"Aleem Gangjee","orcid":"https://orcid.org/0000-0002-5513-7616","observed_orcids":["https://orcid.org/0000-0002-5513-7616"]},"institutions":[{"id":"https://openalex.org/I165102784","display_name":"Duquesne University","ror":"https://ror.org/02336z538","country_code":"US","type":"education","lineage":["https://openalex.org/I165102784"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Aleem Gangjee","raw_affiliation_strings":["Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, Pennsylvania 15282, USA. gangjee@duq.edu","Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, Pennsylvania 15282, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, Pennsylvania 15282, USA. gangjee@duq.edu","institution_ids":["https://openalex.org/I165102784"]},{"raw_affiliation_string":"Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, Pennsylvania 15282, USA","institution_ids":["https://openalex.org/I165102784"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057724028","display_name":"Hiteshkumar D. Jain","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Hiteshkumar Jain","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5087840200","display_name":"Sonali Kurup","orcid":"https://orcid.org/0000-0003-4722-7862","observed_orcids":["https://orcid.org/0000-0003-4722-7862"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Sonali Kurup","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":4.2598,"has_fulltext":false,"cited_by_count":79,"citation_normalized_percentile":{"value":0.94863604,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":86,"max":98},"biblio":{"volume":"8","issue":"2","first_page":"205","last_page":"231"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10274","display_name":"Heterocyclic Compound Synthesis and Bioactivity","score":0.38109999895095825,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},"topics":[{"id":"https://openalex.org/T10274","display_name":"Heterocyclic Compound Synthesis and Bioactivity","score":0.38109999895095825,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.1688999980688095,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12827","display_name":"Biochemical and Molecular Research","score":0.1648000031709671,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/antifolate-drugs","display_name":"antifolate","score":0.9959999918937683},{"id":"https://openalex.org/keywords/thymidylate-synthase-inhibitors","display_name":"thymidylate synthase inhibitors","score":0.9380000233650208},{"id":"https://openalex.org/keywords/dihydrofolate-reductase-inhibitors","display_name":"dihydrofolate reductase inhibitors","score":1.0},{"id":"https://openalex.org/keywords/reduced-folate-carrier","display_name":"reduced folate carrier","score":0.9629999995231628},{"id":"https://openalex.org/keywords/methotrexate","display_name":"methotrexate","score":0.7760000228881836},{"id":"https://openalex.org/keywords/5-fluorouracil","display_name":"5-fluorouracil","score":0.9620000123977661},{"id":"https://openalex.org/keywords/pemetrexed","display_name":"pemetrexed","score":0.9769999980926514},{"id":"https://openalex.org/keywords/raltitrexed","display_name":"raltitrexed","score":0.9829999804496765},{"id":"https://openalex.org/keywords/trimethoprim","display_name":"trimethoprim","score":0.9290000200271606},{"id":"https://openalex.org/keywords/piritrexim","display_name":"piritrexim","score":0.9980000257492065},{"id":"https://openalex.org/keywords/anticancer-agents","display_name":"anticancer agents","score":0.7770000100135803},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.6740000247955322},{"id":"https://openalex.org/keywords/structure-activity-relationship","display_name":"structure-activity relationship","score":0.7710000276565552}],"concepts":[{"id":"https://openalex.org/C28826006","wikidata":"https://www.wikidata.org/wiki/Q33521","display_name":"Applied mathematics","level":1,"score":0.3430917263031006},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.32185035943984985},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.28465038537979126},{"id":"https://openalex.org/C33923547","wikidata":"https://www.wikidata.org/wiki/Q395","display_name":"Mathematics","level":0,"score":0.21955358982086182}],"mesh":[{"descriptor_ui":"D000890","descriptor_name":"Anti-Infective Agents","qualifier_ui":"Q000145","qualifier_name":"classification","is_major_topic":false},{"descriptor_ui":"D000890","descriptor_name":"Anti-Infective Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000890","descriptor_name":"Anti-Infective Agents","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000145","qualifier_name":"classification","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D005493","descriptor_name":"Folic Acid Antagonists","qualifier_ui":"Q000145","qualifier_name":"classification","is_major_topic":false},{"descriptor_ui":"D005493","descriptor_name":"Folic Acid Antagonists","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D005493","descriptor_name":"Folic Acid Antagonists","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009894","descriptor_name":"Opportunistic Infections","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D013237","descriptor_name":"Stereoisomerism","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013329","descriptor_name":"Structure-Activity Relationship","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015394","descriptor_name":"Molecular Structure","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.2174/187152008783497064","doi":"https://doi.org/10.2174/187152008783497064","is_oa":false,"landing_page_url":"https://doi.org/10.2174/187152008783497064","pdf_url":null,"source":{"id":"https://openalex.org/S159246083","display_name":"Anti-Cancer Agents in Medicinal Chemistry","issn_l":"1568-0118","issn":["1568-0118","1871-5206","1875-5968","1875-5992"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-3"],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anti-Cancer Agents in Medicinal Chemistry","raw_type":"journal-article"},{"id":"pmid:18288923","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18288923","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anti-cancer agents in medicinal chemistry","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9391000270843506}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4230809397","https://openalex.org/W4297882644","https://openalex.org/W2087092768","https://openalex.org/W2402116095","https://openalex.org/W2063927417","https://openalex.org/W2400059301","https://openalex.org/W2171490806","https://openalex.org/W1971343016","https://openalex.org/W2040301739","https://openalex.org/W2055706334"],"abstract_inverted_index":{"Antifolates":[0],"that":[1,66,103,138,171],"inhibit":[2,68],"the":[3,30,53,95,153,176,192],"key":[4,173],"enzymes":[5],"thymidylate":[6],"synthase":[7],"(TS)":[8],"and":[9,19,25,35,49,60,70,114,118,126,135,143,168,183,195,200,203,208,214,227],"dihydrofolate":[10],"reductase":[11],"(DHFR)":[12],"have":[13,110,147,164,185],"found":[14],"clinical":[15],"utility":[16],"as":[17,74],"antitumor":[18,75,134,207],"antiopportunistic":[20],"agents.":[21,76],"Methotrexate":[22],"{MTX,":[23],"(1)}":[24],"5-fluorouracil":[26],"(5-FU)":[27],"were":[28,219],"among":[29],"first":[31],"clinically":[32,72,84],"useful":[33,73,85],"DHFR":[34,201],"TS":[36,199],"inhibitors,":[37],"respectively.":[38],"The":[39,224],"development":[40],"of":[41,55,80,179],"resistance":[42,82],"to":[43,83,107,148,206],"5-FU,":[44],"its":[45],"occasional":[46],"unpredictable":[47],"activity":[48],"toxicity":[50],"resulted":[51],"in":[52,175,221,234],"search":[54],"novel":[56,169],"antifolates.":[57],"Pemetrexed":[58],"(4)":[59],"raltitrexed":[61],"(5)":[62],"are":[63,71,130],"newer":[64],"antifolates":[65,86,102,132,163,218,229],"specifically":[67],"TS,":[69,180],"A":[77],"major":[78],"mechanism":[79],"tumor":[81],"is":[87],"based":[88],"on":[89,150],"their":[90,204],"need":[91,106],"for":[92,133,160,198],"polyglutamylation":[93],"via":[94],"enzyme":[96],"folylpoly-gamma-glutamate":[97],"synthetase":[98],"(FPGS).":[99],"Recently,":[100],"classical":[101],"do":[104,145],"not":[105,146],"be":[108,231],"polyglutamylated":[109],"also":[111],"been":[112,165,186],"developed":[113],"include":[115],"plevitrexed":[116],"(6)":[117],"GW1843":[119],"(7).":[120],"Nolatrexed":[121],"(8),":[122],"trimethoprim":[123],"{TMP,":[124],"(11)}":[125],"piritrexim":[127],"{PTX,":[128],"(12)}":[129],"nonclassical":[131],"parasitic":[136,209],"chemotherapy":[137],"passively":[139],"diffuse":[140],"into":[141],"cells":[142],"hence":[144],"depend":[149],"FPGS":[151],"or":[152],"reduced":[154],"folate":[155],"carrier":[156],"(RFC).":[157],"Structural":[158],"requirements":[159,197],"inhibition":[161,202],"with":[162],"studied":[166],"extensively":[167],"agents":[170],"exploit":[172],"interactions":[174],"active":[177],"site":[178],"DHFR,":[181],"FPGS,":[182],"RFC":[184],"proposed.":[187],"This":[188],"two-part":[189],"review":[190],"discusses":[191],"design,":[193],"synthesis":[194],"structural":[196],"relevance":[205],"chemotherapy,":[210],"since":[211],"1996.":[212],"Monocyclic":[213],"6-5":[215],"fused":[216],"bicyclic":[217,226],"discussed":[220,232],"Part":[222,235],"I.":[223],"6-6":[225],"tricyclic":[228],"will":[230],"here":[233],"II.":[236]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2002810554","counts_by_year":[{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":6},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":5},{"year":2013,"cited_by_count":7},{"year":2012,"cited_by_count":4}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
